✦ LIBER ✦

An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer

✍ Scribed by Allen L. Cohn; Grace C. Shumaker; Pankaj Khandelwal; David A. Smith; Marcus A. Neubauer; Nilesh Mehta; Donald Richards; David L. Watkins; Kathy Zhang; Mohamed R. Yassine

Book ID: 116365613
Publisher: CIG Media Group, LP.
Year: 2011
Tongue: English
Weight: 429 KB
Volume: 10
Category: Article
ISSN: 1533-0028
DOI: 10.1016/j.clcc.2011.03.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter, nonrandomized, open-label

A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer

✍ G. Konecny; N. Finkler; P. Lee; A. Yovine; A. Liu; P. Sen; M. Squires; A. Kay 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

3046 POSTER A randomized, open-label pha

3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer

✍ T.E. Ciuleanu; W. Scheithauer; G. Kurteva; J. Ocvirk; I. Koza; D. Papamichael; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

A single-arm, multicenter, open-label ph

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

✍ Christian Wülfing; Jean-Pascal H. Machiels; Dirk J. Richel; Marc-Oliver Grimm; U 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

Re: Phase II Trial of Sorafenib Plus Int

Re: Phase II Trial of Sorafenib Plus Interferon Alfa-2b as First- or Second-Line Therapy in Patients with Metastatic Renal Cell Cancer

✍ Fray F. Marshall 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 108 KB

P51 Randomised, single-centre, phase 2 t

P51 Randomised, single-centre, phase 2 trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer

✍ Y. Chi; J. Wang; Z. Zheng; A. Zhou; L. Yang; T. Qu; W. Jiang; S. Shi; Y. Sun; Y. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

An open-label, single-arm Phase II study

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

✍ Peter G. Rose; Bradley J. Monk; Diane Provencher; Jean Hartney; Philippe Legenne 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB